secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0000784199-24-000207
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net
--------------------------------------------------------------------------------

- Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.
- Purchase option upfront payment reduced from $250M to $175M; net to $135M after loan offset.
- $100M minimum earnout eliminated; earnout now 2.5x incremental year-2 revenue (max $200M).
- Company does not expect material impact on FY2024 guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000207/0000784199-24-000207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000207/aort-20240701.htm
  HTML page:      https://secwatch.observer/filing/0000784199-24-000207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer